Like many other biopharma companies presenting at this year’s J.P. Morgan Healthcare Conference, Eli Lilly took a chance on Tuesday to share its preliminary sales results for 2024. Unfortunately for the company, however, the early glimpse at its fourth-quarter performance
read moreIn response to the anti-vaccine movement in the U.S., CEOs from GSK and Sanofi stressed the need for transparency in discussing the value of vaccines. More: JPM25: GSK, Sanofi CEOs welcome 'transparency' in response to anti-vaccine movement in US Source:
read more
First-in-human trial of PTD802 to commence following UK MHRA approval More: Pheno Therapeutics granted trial authorisation for MS candidate Source: News
read more
Initiative aims to identify plasma-based biomarkers for early detection More: Grifols pioneers high-tech analysis of plasma bank to detect Parkinson’s disease Source: News
read moreAs the J.P. Morgan Healthcare Conference enters its second day, we’re tracking presentations from GSK, Novartis, Sanofi, Eli Lilly and more. More: JPM25, Day 2: Biogen ready to stand its ground in Alzheimer's showdown, CEO says Source: fierce
read moreRegeneron had little explanation for a sequential decline in sales of Eylea HD from $392 million in the third quarter to $305 million in the fourth quarter. More: JPM25: Regeneron CEO says it needs more 'arrows in its quiver' as
read more© 1994 - 2026 B.M. Pharmaceuticals